Fexofenadinen (ing-gú: Fexofenadine, Fexofenadine hydrochloride) iōng Allegra tíng-tíng ê phín-pâi huàn-bē[10] sī tsi̍t-tsióng khòng tsoo-tsit-an [en] io̍h-phín, iōng-teh tī-liâu [en] hue-hún-tsìng [en] hām khí-tshìn-mo̍oh [en] tíng-tíng ê kuè-bín-tsìng [en].[11]

Fexofenadine
Skeletal formula of fexofenadine
Ball-and-stick model of fexofenadine
Clinical data
Trade names Allegra, others
AHFS/Drugs.com Monograph
MedlinePlus a697035
data
Pregnancy
category
Routes of
administration
By mouth
Drug class Antihistamine; H1 receptor antagonist
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability 30–41%[9]
Protein binding 60–70%[8]
Metabolism Hepatic (≤5% of dose)[8]
Elimination half-life 14.4 hours
Excretion Feces (~80%) and urine (~10%) as unchanged drug[8]
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
ECHA InfoCard 100.228.648 Edit this at Wikidata
Chemical and physical data
Formula C32H39NO4
Molar mass 501.67 g·mol−1
3D model (JSmol)
Chirality Racemic mixture
 ☒N☑Y (what is this?)  (verify)

Tsù-kái siu-kái

  1. "Fexofenadine Use During Pregnancy". Drugs.com. 1 April 2019. 26 July 2020 khòaⁿ--ê. 
  2. "Telfast 30mg Film-coated Tablets - Summary of Product Characteristics (SmPC)". (emc). 25 October 2019. 20 June 2021 khòaⁿ--ê. 
  3. "Almerg 180 mg Film-Coated Tablets - Summary of Product Characteristics (SmPC)". (emc). 20 June 2021 khòaⁿ--ê. 
  4. "Fexofenadine Hydrochloride 120 mg Film-Coated Tablets - Summary of Product Characteristics (SmPC)". (emc). 22 March 2021. 20 June 2021 khòaⁿ--ê. 
  5. "Allegra (fexofenadine hydrochloride) tablet, orally disintegrating for oral use Allegra (fexofenadine hydrochloride) tablet, film coated for oral use Allegra (fexofenadine hydrochloride) suspension for oral useInitial U.S. Approval: 1996". DailyMed. 15 December 2008. 13 February 2022 khòaⁿ--ê. 
  6. "Allegra Allergy- fexofenadine hydrochloride tablet, coated". DailyMed. 12 February 2022 khòaⁿ--ê. 
  7. http://products.sanofi.ca/en/allegra.pdf [bare URL PDF]
  8. 8.0 8.1 8.2 Smith, SM; Gums, JG (July 2009). "Fexofenadine: biochemical, pharmacokinetic and pharmacodynamic properties and its unique role in allergic disorders". Expert Opinion on Drug Metabolism & Toxicology. 5 (7): 813–22. doi:10.1517/17425250903044967. PMID 19545214. 
  9. Lappin G, Shishikura Y, Jochemsen R, Weaver RJ, Gesson C, Houston B, Oosterhuis B, Bjerrum OJ, Rowland M, Garner C (May 2010). "Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability". Eur J Pharm Sci. 40 (2): 125–31. doi:10.1016/j.ejps.2010.03.009. PMID 20307657. 
  10. "Fexofenadine - international brand names". Drugs.com. 18 January 2017 khòaⁿ--ê. 
  11. Bachert, C (May 2009). "A review of the efficacy of desloratadine, fexofenadine, and levocetirizine in the treatment of nasal congestion in patients with allergic rhinitis". Clin Ther. 31 (5): 921–44. doi:10.1016/j.clinthera.2009.05.017. PMID 19539095. 

Tsham-ua̍t siu-kái

Guā-pōo lên-ket siu-kái